MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Panagene
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Panagene Reaches Settlement of Patent Infringement Cases with Biosynthesis - Panagene and Biosynthesis, Inc. (Lewisville, Texas) have agreed to settle Panagene’s allegations of patent infringement that were pending in the United States District Court for the Eastern District of Texas - Panagene.com
Panagene Reaches Settlement of Patent Infringement Cases with Biosynthesis

 

NewswireToday - /newswire/ - Daejeon, Chungchungnamdo, Korea (South), 2012/12/20 - Panagene and Biosynthesis, Inc. (Lewisville, Texas) have agreed to settle Panagene’s allegations of patent infringement that were pending in the United States District Court for the Eastern District of Texas - Panagene.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Panagene, Inc. announced today that Panagene and Biosynthesis, Inc. (Lewisville, Texas) have agreed to settle Panagene’s allegations of patent infringement that were pending in the United States District Court for the Eastern District of Texas. The terms of the settlement include Biosynthesis’ undisclosed payments of past damages and stopping immediately all PNA products sales and PNA-related services. Panagene alleged that Biosynthesis’ PNA products and PNA-related services infringe two patents exclusively licensed by Panagene: United States Patent Nos. 6,395, 474 and 7,378, 485. These patents cover multiple aspects of PNA (Peptide nucleic acids, artificial DNA) material and technology, including PNA oligomers, PNA monomers, and PNA uses in diagnostics.

“Intellectual properties are keys of advancing technology and Panagene is investing significant resources to develop and license in new technologies to support the needs of the advanced PNA diagnostic for personalized medicine and therapeutic market. We have, and will continue to enforce our patent rights,” said Dr. Sungkee Kim, President and CEO of Panagene, Inc. “Panagene is pleased to have achieved a favorable resolution of the patent infringement action against Biosynthesis.”

About Panagene

Panagene, Inc. (panagene.com), a listed company headquartered in Daejeon, Korea, is exclusively licensed PNA supplier worldwide. Panagene developed and patented efficient PNA production processes for PNA oligomers in high purity and large quantities. Panagene have also developed PNA-based diagnostic technology such as PNAClamp™ and PANArray™ (PNA microarray chip) and delivers highly sensitive and specific diagnostic products for detections of gene mutations and genotypes of pathogens.

Panagene has distributors in the U.S., Austria, Belgium, Bulgaria, China, Czech Republic, India, Iran, Israel, Japan, Spain, Taiwan, and UK.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Panagene

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Panagene Reaches Settlement of Patent Infringement Cases with Biosynthesis

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Tae Kim - Panagene.com 
805-480-4897 info[.]panagene.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Panagene securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Panagene / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®
Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs
Global Pharmaceutical Contract Manufacturing Organization Market to Reach 2.14 Billion by 2024 Finds Frost & Sullivan
Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy
Human Microbiome Market to Reach .08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics Finds Frost & Sullivan
BASF Launches Hepacor in Switzerland for the Dietary Management of Non-Alcoholic Fatty Liver Disease
FDA Grants Priority Review to Genentech’s Risdiplam for Spinal Muscular Atrophy
Ipsen Presents New Analyses Utilizing Modern Data Mining Approaches At ISPOR Europe 2019
Global Opioids Drugs Market is Projected to Grow At a CAGR of 2.52% by 2027 Reports Inkwood Research

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit Apex Watercraft

Visit  JobsWare.com





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)